Masimo Co. (NASDAQ:MASI) Shares Bought by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC raised its position in shares of Masimo Co. (NASDAQ:MASI) by 40.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 224 shares of the medical equipment provider’s stock after acquiring an additional 64 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Masimo were worth $37,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. KBC Group NV lifted its holdings in Masimo by 17.3% in the 3rd quarter. KBC Group NV now owns 1,280 shares of the medical equipment provider’s stock valued at $171,000 after purchasing an additional 189 shares in the last quarter. CIBC Asset Management Inc purchased a new position in shares of Masimo in the third quarter worth about $206,000. Empowered Funds LLC acquired a new position in Masimo during the third quarter worth about $279,000. Quest Partners LLC grew its stake in Masimo by 8,360.0% during the 3rd quarter. Quest Partners LLC now owns 2,115 shares of the medical equipment provider’s stock valued at $282,000 after acquiring an additional 2,090 shares in the last quarter. Finally, Avior Wealth Management LLC raised its holdings in Masimo by 16.5% in the 3rd quarter. Avior Wealth Management LLC now owns 5,731 shares of the medical equipment provider’s stock valued at $764,000 after acquiring an additional 812 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Trading Down 1.9 %

NASDAQ MASI opened at $169.50 on Friday. The firm’s 50-day moving average is $175.00 and its two-hundred day moving average is $158.86. The stock has a market capitalization of $9.14 billion, a P/E ratio of 116.90 and a beta of 1.04. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million. On average, sell-side analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price target (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Piper Sandler upped their target price on Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Raymond James boosted their price target on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Finally, Wells Fargo & Company raised their price objective on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.

Insider Activity at Masimo

In related news, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the sale, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by company insiders.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.